Articles Referencing VPHM
ViroPharma Reports Loss in 1Q - Analyst Blog
5/2/2013, 1:53 pm from Zacks.com in Investing, Business, Stocks
ViroPharma Inc.'s ( VPHM ) first quarter
2013 adjusted loss (excluding special items but including
stock-based compensation) came in at 7 cents per share compared to
year-ago earnings... Read >>
Optimer's Dificid Cleared Down Under - Analyst Blog
5/1/2013, 6:28 pm from Zacks.com in Investing, Business, Stocks
Optimer Pharmaceuticals ( OPTR ) received
encouraging news recently when the Australian regulatory body
(Australian Therapeutic Goods Administration) cleared its drug
Dificid (fidaxomicin).... Read >>
Pipeline Progresses at ViroPharma - Analyst Blog
4/23/2013, 6:11 pm from Zacks.com in Investing, Business, Stocks
ViroPharma Incorporated ( VPHM ) recently
announced results from a phase II study of its candidate VP20621
(non-toxigenic Clostridium difficile), which is being developed to
prevent... Read >>
ViroPharma Tops on All Fronts - Analyst Blog
2/28/2013, 4:38 pm from Zacks.com in Investing, Business, Stocks
ViroPharma Inc.'s ( VPHM ) fourth quarter
2012 adjusted earnings (including stock-based compensation) of 3
cents per share were above the Zacks Consensus Estimate of a penny
but... Read >>
Data on ViroPharma's Cinryze - Analyst Blog
1/18/2013, 6:13 pm from Zacks.com in Investing, Business, Stocks
ViroPharma ( VPHM ) recently
announced that The Journal of Pediatrics published data in
an article on Jan 14, 2013, which demonstrated that key product
Cinryze (C1 esterase inhibitor... Read >>
One Biotech Stock Investors are Unfairly Ignoring
1/15/2013, 9:00 am from Benzinga in Investing, Investing Ideas
Shares of biotech company Halozyme Therapeutics (NASDAQ: HALO ) were unchanged
in pre-market trading on Tuesday following Monday's gain of more
than 15 percent. Investors bid up the stock... Read >>
Upbeat 2013 from ViroPharma - Analyst Blog
1/8/2013, 5:29 pm from Zacks.com in Investing, Business, Stocks
ViroPharma Incorporated ( VPHM )
recently provided guidance for 2013. ViroPharma expects net
product sales between $450 million and $475 million in 2013 on a
worldwide basis.... Read >>
MDCO Scores in SOLO-1 Trial - Analyst Blog
12/24/2012, 11:40 am from Zacks.com in Investing, Business, Stocks
The Medicines Company ( MDCO )
recently received good news with the company announcing positive
results on its phase III antibiotic candidate, oritavancin.
Oritavancin was being evaluated... Read >>
Pre-Market Most Active for Aug 13, 2012 : SIRI, AMKR, FNP, DHI, HST, TC, LEN, CDNS, LXP, VRSN, CIEN, VPHM
8/13/2012, 8:36 am from NASDAQ.com News in News Headlines, Pre-market Most Active
The NASDAQ 100
Pre-Market Indicator is up 4.24 to 2,727.2. The total
Pre-Market volume is currently 21,735,073 shares traded.
The following are the
most active stocks for the pre-market... Read >>
SPX Breaks 1,400 as Bulls Challenge Technical Hurdles
8/7/2012, 4:35 pm from Schaeffer's Investment Research in Investing, Options
"After the past two days' price action ,
the S&P 500 Index (SPX) has once again made a new two-month
high, and continued its strong trend off its June bottom,"... Read >>
A Legendary Biotech Investor Just Spent $14 Million on this Stock
4/17/2012, 11:30 am from David Sterman in Investing, Investing Ideas
Randal J. Kirk is beside himself right now. The legendary
biotech investor, who is now worth more than $2 billion, made a
rare misstep by plunking down $14 million (at $10.61 a share) on
... Read >>
Pre-Market Most Active for Apr 10, 2012 : ALU, BAC, SIRI, SVU, ERT, VVUS, VPHM, SNY, CVX, STD, AAPL, QQQ
4/10/2012, 8:40 am from NASDAQ.com News in News Headlines, Investing
The NASDAQ 100 Pre-Market Indicator is up 8.82 to 2,748.8. The
total Pre-Market volume is currently 10,909,841 shares traded.
The following are the most active stocks for the... Read >>
10 Rallying Stocks Generating Significant Levered Free Cash Flow
4/19/2011, 12:03 pm from Kapitall in Investing, Investing Ideas, Stocks
If you are an equity investor looking to go with the trend, the following list might provide you with an interesting starting point for your own analysis. To compile this list, focused on... Read >>